WO2008075649A1 - Boisson, aliment, alicament, composition médicinale et procédé destinés à favoriser la croissance capillaire - Google Patents

Boisson, aliment, alicament, composition médicinale et procédé destinés à favoriser la croissance capillaire Download PDF

Info

Publication number
WO2008075649A1
WO2008075649A1 PCT/JP2007/074236 JP2007074236W WO2008075649A1 WO 2008075649 A1 WO2008075649 A1 WO 2008075649A1 JP 2007074236 W JP2007074236 W JP 2007074236W WO 2008075649 A1 WO2008075649 A1 WO 2008075649A1
Authority
WO
WIPO (PCT)
Prior art keywords
hair growth
vitamin
extract
group
pharmaceutical composition
Prior art date
Application number
PCT/JP2007/074236
Other languages
English (en)
Japanese (ja)
Inventor
Osamu Masaki
Original Assignee
Mmt Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/JP2007/050913 external-priority patent/WO2008075466A1/fr
Application filed by Mmt Co., Ltd. filed Critical Mmt Co., Ltd.
Priority to JP2008550140A priority Critical patent/JPWO2008075649A1/ja
Publication of WO2008075649A1 publication Critical patent/WO2008075649A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/287—Chrysanthemum, e.g. daisy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9741—Pteridophyta [ferns]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Definitions

  • the present invention relates to a food for promoting hair growth, a quasi-drug for promoting hair growth, and a pharmaceutical composition for promoting hair growth, which contain an extract of a asteraceae plant or a component thereof, and more specifically, a feverfew extract.
  • the present invention provides a hair growth-promoting food, a quasi-drug for hair growth promotion, and a pharmaceutical composition for hair growth promotion, comprising a product or a sesquiterpene ratatatone, specifically, baltenolide.
  • the present invention includes feverfew extract or sesquiterpene ratatones, specifically parthenolides and B-group vitamin-containing foods and drinks, quasi-drugs for promoting hair growth and pharmaceutical compositions for promoting hair growth.
  • the present invention also provides a method for promoting hair growth using an extract of Asteraceae plants or components thereof, particularly feverfew extract or sesquiterpene ratatatone, specifically, parthenolide.
  • the present invention also provides a method for promoting hair growth using extracts of Asteraceae plants or components thereof, particularly feverfew extract or sesquiterpene ratatones, in particular, barthenolide and group B vitamins.
  • alopecia Many people suffer from alopecia. For example, hair loss due to accidents, alopecia areata due to stress, hair loss due to aging, young hugging, etc., there are various symptoms of alopecia.
  • Various drugs, quasi-drugs, or cosmetics have been developed for the purpose of suppressing hair loss or for hair growth, hair growth or hair growth.
  • hair growth promoting components used in pharmaceuticals blood circulation promoters and vasodilators such as vitamin E derivatives, minoxidil, and pepper extract are known.
  • blood circulation promoters and vasodilators such as vitamin E derivatives, minoxidil, and pepper extract are known.
  • the doses of these substances are limited from the viewpoint of safety and side effects, so that sufficient action and effects are often not obtained.
  • Patent Document 1 JP 2000-290146 A
  • an extract of a asteraceae plant particularly a feverfew extract and a sesquiterpene ratataton, which is a component thereof, and more specifically, baltenolide is haired. It has been found that it has a promoting effect. Furthermore, the present inventors have shown that hair growth occurs when Group B vitamins are used in combination with an extract of the Asteraceae plant, in particular feverfew extract and its component sesquiterpene rataton, in particular, barthenolide. It was found that the promotion effect becomes even more pronounced. Based on these findings, the present inventors have completed the present invention.
  • the present invention provides:
  • Food and drink for promoting hair growth comprising an extract of Asteraceae plants
  • a quasi-drug for promoting hair growth comprising an extract of a asteraceae plant
  • a pharmaceutical composition for promoting hair growth comprising an extract of a asteraceae plant
  • a pharmaceutical composition for promoting hair growth comprising valenolide
  • Animal feed or veterinary pharmaceutical composition for promoting hair growth comprising an extract of Asteraceae plants;
  • a method for promoting hair growth comprising administering or feeding a Compositae plant extract
  • a method for promoting hair growth comprising administering or feeding baltenolide
  • a food and drink, a quasi-drug, and a pharmaceutical composition for promoting hair growth for promoting hair growth which are reliable and have excellent safety effects, can be obtained. Furthermore, according to the present invention, there is provided a method for promoting hair growth that is reliable and excellent in the effect of increasing safety.
  • FIG. 1 is a photograph showing hair regeneration over time in mice administered orally with barthenolide.
  • Fig. 2 is a photograph showing hair regeneration over time in mice orally administered with feverfew extract.
  • FIG. 3 is a photograph showing hair regeneration over time in mice orally administered with 0.5% aqueous solution of methylcellulose (control).
  • FIG. 4 is a graph showing the change over time in the ratio of the area of regenerated hair to the shaved area of mice orally administered with barthenolide, feverfew and control.
  • FIG. 5 is a photograph showing hair regeneration over time in mice coated with valthenolide.
  • Fig. 6 is a photograph showing hair regeneration over time in mice coated with feverfew extract.
  • FIG. 7 is a photograph showing hair regeneration over time in mice coated with 0.5% aqueous solution of methylcellulose (control).
  • FIG. 8 is a graph showing the change over time in the ratio of the regenerated hair area to the shaved area of mice to which parthenolide, feverfew and control were applied.
  • Fig. 9-1 is a photograph showing hair regeneration in volunteers taking orally administered feverfew extract.
  • the monitor number is a number assigned to each volunteer. The pictures show the 0th, 1st, 2nd and 3rd months from the left.
  • Fig. 9-2 is a photograph showing hair regeneration in volunteers who took (oral administration) feverfew extract.
  • the monitor number is a number assigned to each volunteer. The pictures show the 0th, 1st, 2nd and 3rd months from the left.
  • Fig. 10-1 is a photograph showing hair regeneration in volunteers who took feverfew extract and vitamins B2 and B6 (oral administration).
  • the monitor number is a number assigned to each volunteer. The pictures show the 0th, 1st, 2nd and 3rd months from the left.
  • Fig. 10-2 is a photograph showing hair regeneration in volunteers who took feverfew extract and vitamins B2 and B6 (oral administration).
  • the monitor number is a number assigned to each volunteer. The pictures show the 0th, 1st, 2nd and 3rd months from the left.
  • FIG. 11 1 is a photograph showing hair regeneration in a volunteer who applied feverfew extract to the scalp.
  • the monitor number is a number assigned to each volunteer. The pictures show the 0th, 1st, 2nd and 3rd months from the left.
  • Fig. 11 2 is a photograph showing hair regeneration in volunteers with feverfew extract applied to the scalp.
  • the monitor number is a number assigned to each volunteer. The pictures show the 0th, 1st, 2nd and 3rd months from the left.
  • the present invention relates to a food and drink for promoting hair growth, which contains an extract of a asteraceae plant.
  • the plant extract used in the food and drink of the present invention is not particularly limited as long as it is a plant extract containing sesquiterpene ratatones.
  • Examples of plants rich in sesquiterpene ratatones include asteraceae plants, such as plants belonging to the genus Artemisia and dandelions. Sesquiterpene ratatones are asteraceae plants It is abundant in things, especially baltenolide. So far, it has been reported that extracts of asteraceae plants such as mugwort and feverfew and their component baltenolide have various physiological effects such as anti-inflammatory effects. However, it has been reported so far that Asteraceae plants, in particular feverfew extract and sesquiterpene ratatones, in particular parthenolide, show hair growth-promoting action!
  • promoting hair growth refers to a condition such as alopecia, hair loss, and other conditions that require hair growth, hair growth, hair restoration, hair growth or hair regeneration, or hair loss prevention. It means hair growth action, hair growth action, hair nourishing action, hair thickening action, hair loss prevention action, etc.
  • the asteraceae plant used in the food and drink of the present invention is preferably sesquiterpene ratatones, particularly those having a high parthenolide content and plants.
  • examples of such plants include plants belonging to the genus Artemisia, particularly preferably Tanacetum parthenium (also referred to as fever fu). Therefore, particularly preferred Asteraceae extracts used in the present invention are feverfew extracts. Feverfew plants, especially leaves, usually contain about 0.2 to 0.9% of barthenolide.
  • an extract of Asteraceae plants, especially feverfew extract and its component sesquiterpene lactone specifically when applying orally ingesting valthenolide to the affected area. Particularly excellent hair growth promoting action was confirmed.
  • An extract of the Asteraceae plant can be obtained by a known method.
  • the extraction part may be any part as long as it is an above-ground part of the plant, but a preferable extraction part is a leaf.
  • the extract may be obtained by immersing the plant in a solvent as it is, but the extraction efficiency is higher when the contents are extracted after crushing.
  • the plant may be raw or dried. For drying, a known drying method such as warm air drying or air drying can be used. Various types of plant crushing means can be used.
  • Suspension 'Extraction media can be water, ether, methanol, ethanol, or a mixture of ethanol and water. Examples include compounds.
  • the suspension medium is preferably less toxic or non-toxic. From this point of view, water, ethanol, or a mixture of ethanol and water is particularly preferred as a suspension 'extraction medium.
  • Extraction conditions such as temperature, pressure, and time during suspension extraction can be selected according to the type and amount of plants.
  • the above-ground parts of plants for example, leaves and stems, are directly dried by a known drying method such as hot air drying or air drying, and pulverized to obtain a food or drink or pharmaceutical composition of the present invention. May be used for things.
  • the obtained extract can be decanted, filtered, or centrifuged to remove solids and particulate matter.
  • the obtained extract may be concentrated by a known method such as evaporation. Further, the obtained extract may be further purified by a known method, for example, various chromatography or precipitation methods.
  • the plant extract used in the food and drink of the present invention can be obtained as described above.
  • the power nashigiku extract is also commercially available, and this may be used.
  • These extracts can be made into various forms according to usage forms, purposes, etc., and can be prepared into liquids, semi-solids, powders (for example, freeze-dried powders, etc.).
  • An Asteraceae plant extract can be blended with various foods to obtain the foods and drinks of the present invention.
  • These asteraceae plant extracts are of low toxicity or non-toxic because they are derived from natural products, and can be incorporated into any food or drink.
  • the extract may be blended in juices or herbal seasonings.
  • the food and drink of the present invention can be a health food, a functional nutritional food, or a food for specified health use (so-called “tokuho”).
  • supplements are mentioned as a preferred form of the food and drink of the present invention.
  • the supplement may be in any shape that can be taken orally, such as tablets, capsules, granules, and powders (e.g., freeze-dried powder). Etc.), suspension, drink, elixir, drop, wearable form, jelly form and the like.
  • These supplements can be manufactured in accordance with the processes used in the food and pharmaceutical fields. For example, manufacturing tablet-shaped supplements In the case of pharmacology, it is possible to use general processes such as mixing, drying, and tableting used in the pharmaceutical field. For example, in the case of a capsule form, a general process such as mixing and encapsulating can be used.
  • Soft capsules and hard capsules can also be appropriately selected according to the purpose.
  • liquid supplements water, ethanol, etc. have low toxicity, and the extract can be dissolved / suspended in a medium.
  • powder and granule supplements it is also possible to use conventional processes such as mixing, drying, grinding and sieving.
  • a carrier or excipient is used in the production of supplements, the type and amount can be selected according to the practice in the pharmaceutical field.
  • solid carriers or excipients include talc, carboxymethylcellulose, sucrose, and wheat flour.
  • the liquid carrier include water, ethanol, and edible fats and oils.
  • the food and drink or supplement of the present invention may contain sesquiterpene ratatones, preferably parthenolide, instead of or in addition to the above-mentioned Asteraceae plant extract. It may be a baltenolide crude product or a purified product. Valtenolide may be purified or isolated from the above extract, for example. Valthenolide may be a chemically synthesized product.
  • the food or drink of the present invention requires all kinds of alopecia such as young hugging and alopecia areata, hair loss, other hair growth promotion, hair growth, hair restoration, hair growth or hair regeneration, or prevention of hair loss It is effective against the state. Moreover, the food and drink and the supplement of the present invention are effective regardless of gender.
  • B group vitamins include vitamin Bl, vitamin B2, vitamin B6, vitamin B12, niacin, pantothenic acid, folic acid and biotin.
  • group B vitamins includes vitamin Bl, vitamin B2, vitamin B6, vitamin B12, niacin, pantothenic acid, folic acid and biotin, and their derivatives.
  • one or more of these group B vitamins can be used.
  • B group vitamins are vitamin B2 and It is vitamin B6, and it is more preferable to use them in combination.
  • the amount of the Asteraceae plant extract (in the case of baltenolide content 0 ⁇ 9% (w / w)) ingested per day in the food or drink of the present invention is the amount of sesquite contained in the extract.
  • feverfew extract for adults (weight 70 kg), it is common to take about 0.05 g to 50 g per day, and it is appropriate to take about 0.15 g to 15 g. 0 It is more appropriate to take about 5g to 3.Og.
  • the intake of baltenolide is generally about 0.45 mg to 450 mg per day for an adult (70 kg body weight). It is appropriate to take about 35 mg to 135 mg, and more preferably about 4.5 to 27 mg. The amount of these intakes can be increased or decreased depending on conditions such as a site where the desired hair growth promoting effect is desired. You can also take these intakes once or multiple times a day.
  • the amount of group B vitamins consumed per day contained in the food or drink of the present invention is about 4 mg to 10 mg, preferably 5 mg for each of the above eight vitamins if it is an adult (weight 70 kg). It is about ⁇ 8mg.
  • an adult (70 kg body weight) may take 6 mg of vitamin B2 and 6 mg of vitamin B6 per day with asteraceae extracts and parthenolide.
  • the B and group vitamins may be ingested separately from the food and drink or the supplement of the present invention, and the intake amount of the B group vitamins is also the same as described above. These intakes can be increased or decreased depending on conditions such as a site where the desired hair growth promoting effect is desired. These intakes can be taken once or multiple times a day.
  • asteraceae plant extracts, barthenolide, and one or more other active ingredients may be mixed in addition to the B group vitamin! / ! / ⁇ For example, vitamin E and its derivatives, ⁇ -oryzanol, / 3-strength rotin, soybean saponin, Nattokinase, flavonoids, gingerol, gallic sulfide, capsaicin, scordin, rutin, ⁇ -linolenic acid, keihi, carpronium chloride, tocopherol acetate Blood circulation promoting substances such as vitamin ⁇ ⁇ ⁇ ⁇ , vitamin C, vitamin D, calcium, royal jelly, Inositol, Coenzyme A, Coenzyme Q10, Zinc, Sulfur, Selenium, Collagen, Gelatin, Methionine, EPA, Chondroitinic acid, Nettle, Olives, Seaweed extract, Venetian, Rosemary,
  • the intake of these active ingredients and the intake of the food and drink of the present invention may be used in combination.
  • the present invention provides a quasi-drug for promoting hair growth, comprising an extract of a asteraceae plant.
  • the extract of Asteraceae used in the quasi-drug of the present invention is as described above.
  • a form of quasi-drug a cosmetic form is common. Specifically, it can be in the form of lotion, cream, liniment, ointment, spray, bam, shampoo, tonic, genore, wax, treatment, knock, hair foam and the like. Apply force and quasi-drugs to areas where hair growth is desired, such as the scalp.
  • the quasi-drug of the present invention includes components that promote the penetration of an active ingredient such as an extract of asteraceae or valthenolide, such as ethanol, glycerin, chitofilmer, propylene glycol, glycyrrhizic acid, and the like. Fragrances and coloring agents.
  • an active ingredient such as an extract of asteraceae or valthenolide, such as ethanol, glycerin, chitofilmer, propylene glycol, glycyrrhizic acid, and the like. Fragrances and coloring agents.
  • the quasi drug of the present invention may contain sesquiterpene ratatatone, preferably parthenolide, instead of or in addition to the above-mentioned asteraceae plant extract. It may be a crude product of baltenolide or a refined product. Valtenolide may be purified or isolated from the above extract, for example. Valthenolide may be a chemically synthesized product.
  • the quasi-drug of the present invention requires all types of alopecia such as young hugging and alopecia areata, hair loss, other hair growth promotion, hair growth, hair restoration, hair growth or hair regeneration, or prevention of hair loss It is effective against the state.
  • the quasi-drug of the present invention can be applied to any part of the skin.
  • the quasi-drug of the present invention is effective regardless of gender.
  • the above-mentioned effects of the quasi drug of the present invention are obtained by combining the quasi drug of the present invention with a group B vitamin. It becomes even more prominent by making it.
  • a quasi-drug containing the asteraceae plant extract of the present invention may be mixed with a group B vitamin or may be used separately.
  • group B vitamins can be used.
  • Preferred group B vitamins are vitamin B2 and vitamin B6, and it is more preferable to use them in combination.
  • the application amount of the Asteraceae extract per day is: It depends on the amount of sesquiterpene ratatones, especially valenolide, contained in the extract.
  • feverfew extract it is common to apply about 0.05 to 50g per day for adults (weight 70kg), and it is appropriate to apply about 0.15 to 15g. It is more appropriate to apply about 0.5 g to 3. Og.
  • baltenolide when baltenolide is used in the quasi-drug of the present invention, the applied amount of baltenolide is generally about 0.45 mg to 450 mg per day for an adult (70 kg body weight). It is appropriate to apply about 35 mg to about 135 mg, and more suitably about 4.5 mg to 27 mg. These application amounts can be increased or decreased depending on conditions such as the desired hair growth promoting effect and application site. In addition, these doses can be applied to the necessary site once or multiple times a day.
  • the amount of vitamin B per day contained in the quasi-drug of the present invention is an adult (70 kg body weight) for each of the above eight vitamins: 4 mg to about! O mg, preferably about 5 mg to It is about 8mg.
  • 6 mg vitamin B2 and 6 mg vitamin B6 per day for adults (70 kg body weight) may be used with asteraceae plant extracts and parthenolides.
  • the B group vitamin may be used separately from the quasi-drug of the present invention, and the dose of the B group vitamin is also the same as described above. These doses can be increased or decreased depending on conditions such as the desired hair growth promoting effect and the site where the effect is desired. These doses can be used once a day or divided into multiple doses.
  • one or more other active ingredients are mixed with the power of the asteraceae plant extract, baltenolide and group B vitamins! / Yo! /
  • a quasi-drug of the present invention may be used by a person who has already undergone treatment for alopecia, hair removal, other hair growth promotion, hair growth, hair growth, hair growth or hair regeneration, or a condition that requires hair loss prevention. By applying, it is possible to promote the therapeutic effect.
  • the quasi-drug of the present invention may be in a form that can be taken from the mouth, such as a drink form.
  • the present invention provides a pharmaceutical composition for promoting hair growth, comprising an extract of a asteraceae plant.
  • the extract of Asteraceae used in the pharmaceutical composition of the present invention is as described above.
  • the pharmaceutical composition of the present invention can be processed into various dosage forms. As described above, asteraceae extracts, particularly feverfew extracts or valenolides, have hair growth promoting effects not only when applied to the skin but also when administered orally. When the pharmaceutical composition of the present invention is applied to the skin, it can be applied to any site.
  • the pharmaceutical composition of the present invention to be orally administered can be produced by a known means' method. It is possible to use known carriers and excipients used in the pharmaceutical composition of the present invention.
  • the dosage form of the pharmaceutical composition of the present invention to be administered orally includes tablets, capsules, granules, powders (eg freeze-dried powder), suspensions, drinks, elixirs, drops, sublingual tablets, chewable forms, jelly It may be a shape such as a shape.
  • general processes such as mixing, drying, and tableting used in the pharmaceutical field.
  • a general process such as mixing and encapsulation can be used.
  • Soft capsules and hard capsules It can be appropriately selected according to the purpose.
  • the extract of asteraceae or barthenolide must be dissolved and / or suspended in a low-toxic or non-toxic medium such as water, glycerol, ethanol or edible oil.
  • Power S can be.
  • To produce powder and granule oral dosage forms it is still possible to use conventional processes such as mixing, drying, grinding and sieving.
  • carriers and excipients are usually used. These types and amounts can be selected in accordance with pharmaceutical practice. Examples of solid carriers or excipients include talc, carboxymethylcellulose, sucrose, flour, and starch. Examples of the liquid carrier include water, glycerol, ethanol, edible oil and fat, and syrup.
  • These oral pharmaceutical compositions may contain conventional ingredients such as fragrances and coloring agents.
  • the pharmaceutical composition of the present invention may be applied to the skin by application, spraying, etc., for example, lotion, cream, ointment, liniment, spray, balm, shampoo, tonic, jewel, It can be a dosage form such as wax, treatment, knock, hair foam.
  • a force and dermal application form can be produced by known means.
  • the lotion can be produced by dissolving or suspending an Asteraceae extract or valthenolide in an aqueous carrier such as water or ethanol.
  • the spray can be obtained by filling a known spraying device with a liquid obtained by dissolving or suspending an Asteraceae extract or valthenolide.
  • Creams and ointments can be produced using vaseline, paraffin, lanolin, mouth, other fats and oils as a base material.
  • Other skin application dosage forms are also known and can be produced by known methods.
  • These skin-applied pharmaceutical compositions may contain conventional ingredients such as fragrances and coloring agents.
  • these dermatological pharmaceutical compositions include substances that promote the penetration of active substances such as asteraceae plant extracts or valthenolides or group B vitamins into the skin, such as ethanol, glycerin, chitofilmer, etc. May be included.
  • the pharmaceutical composition of the present invention can be administered by injection or infusion. Methods for producing injectable preparations and infusion preparations are known. For example, the ability to obtain these simultaneous IJs by dissolving the active ingredient in an injectable carrier such as physiological saline or distilled water. it can.
  • the pharmaceutical composition of the present invention may be used in place of or in addition to the above Asteraceae plant extract.
  • sesquiterpene ratatones preferably parthenolide
  • the barthenolide may be a crude product or a purified product, but highly purified parthenolide is particularly preferred.
  • Valtenolide may be purified or isolated from the above extract, for example.
  • Parthenolide may be a chemically synthesized product.
  • the pharmaceutical composition of the present invention is effective for all types of alopecia, hair loss, other hair growth promotion, hair growth, hair restoration, hair growth or hair regeneration, or a condition requiring hair loss prevention. .
  • the pharmaceutical composition of the present invention is effective regardless of gender.
  • a pharmaceutical composition containing the asteraceae plant extract of the present invention may be used as a mixture of group B vitamins or may be used separately.
  • group B vitamins can be used.
  • Preferred group B vitamins are vitamin B2 and vitamin B6, and it is more preferable to use them in combination.
  • the dosage of the asteraceae plant extract per day is determined by extraction.
  • the amount of feverfew extract to be administered as the pharmaceutical composition of the present invention is generally about 0.05 to 50 g per day for an adult (body weight 70 kg) and about 0.05 to 50 g for oral administration. Yes, it is appropriate to administer about 0.15 g to 15 g, and it is more appropriate to administer about 0.5 g to 3. Og.
  • the amount of feverfew extract (in the case of valtenolide content 0.9% (w / w)) administered as the pharmaceutical composition of the present invention is 1 day for adults (body weight 70 kg), and for skin application. In general, about 0.05 to 50 g is applied, about 0.15 to about 15 g is appropriate, and about 0.5 to about 3 Og is more appropriate.
  • the dose of parthenolide is about 0.45 mg to 450 mg per day for an adult (body weight 70 kg). 1. It is appropriate to administer about 35 mg to 135 mg, and more suitably about 4.5 mg to 27 mg.
  • the amount of valtenolide applied is an adult ( In the case of body weight 70 kg), it is common to apply about 0 ⁇ 45 mg to 450 mg per day, 1. 35 mg to; force of applying about 135 mg S is appropriate, and about 4.5 mg to 27 mg is applied It is more appropriate to do this.
  • These doses or applied doses can be increased or decreased depending on conditions such as the intended hair growth promoting effect and application site. These doses can be administered or applied once a day or divided into multiple doses.
  • the amount of vitamin B per day contained in the pharmaceutical composition of the present invention is an adult (body weight 70 kg), about 4 mg to each of the above 8 vitamins;! Omg, preferably 5 mg to 8 mg Degree.
  • 6 mg vitamin B2 and 6 mg vitamin B6 per day for adults (70 kg body weight) may be used with asteraceae plant extracts and parthenolides.
  • the group B vitamin may be used separately from the pharmaceutical composition of the present invention, and the dose of the group B vitamin is the same as described above. These doses can be increased or decreased depending on conditions such as the desired hair growth promoting effect and the site where the effect is desired. These doses can be used once a day or divided into multiple doses.
  • one or more other active ingredients may be mixed with the asteraceae plant extract, valthenolide, and the power of group B vitamins! / ! /
  • vitamin E and its derivatives for example, vitamin E and its derivatives, ⁇ —oryzanol, / 3 striking rotin, soy saponin, Nattokinase, flavonoid, gingerol, sulfide, capsaicin, scordin, noretin , ⁇ -linolenic acid, keihi, carpronium chloride, tocopherol acetate, or other blood circulation promoters, or assembly extract, carrot extract, vitamin ⁇ , inositol, coenzyme ⁇ , coenzyme Q10, zinc, sulfur, selenium, collagen, gelatin, methionine , Chondroitin sulfate, plant sterol, nettle genus, white birch, horsetail, saw palme
  • hair growth promoting substances such as assembly extract, carrot extract, carpronium chloride, glyceride pentadecanoate, minoxidil, or vitamin E and its derivatives, pepper extract, assembly extract, sage extract, It may contain a blood circulation promoting substance such as Al Niki force extract or Hamamelis extract, or a bactericidal agent or moisturizing agent.
  • a blood circulation promoting substance such as Al Niki force extract or Hamamelis extract, or a bactericidal agent or moisturizing agent.
  • the administration or application of these active ingredients and the book You may use together application of the pharmaceutical composition of invention.
  • the pharmaceutical composition of the present invention is applied to a person who has already undergone treatment for alopecia, hair loss, other hair growth promotion, hair growth, hair nourishment, hair growth or hair regeneration, or a condition requiring hair loss prevention. Therefore, the therapeutic effect can be promoted.
  • the present invention provides, in a further aspect, a method for promoting hair growth, characterized by administering or ingesting an Asteraceae extract, preferably feverfew extract, or a sesquiterpene rataton, preferably baltenolide.
  • an Asteraceae extract preferably feverfew extract, or a sesquiterpene rataton, preferably baltenolide.
  • feverfew extract or valenolide may be applied as a quasi-drug that may be consumed as a food or drink or a supplement, or may be administered or applied as a pharmaceutical composition.
  • the dosage of the Asteraceae extract, preferably feverfew extract, or barthenolide in the method is as described above.
  • the typical administration method of the Asteraceae plant extract, preferably feverfew extract or baltenolide in the method is oral administration and application to the skin, but is not limited to these administration methods.
  • the method for promoting hair growth of the present invention is effective for both men and women, and is also effective for animals other than humans.
  • the hair growth promoting method of the present invention may be used in combination with other hair growth promoting methods.
  • the hair growth-promoting effect of the above-described method of the present invention can be further enhanced by administering or ingesting a group B vitamin in combination.
  • Asteraceae plant extracts and Group B vitamins may be used simultaneously or separately.
  • the amounts used of the Asteraceae plant extract and Group B vitamins in the above method are as described for the foods, beverages, quasi drugs and pharmaceutical compositions of the present invention.
  • an active ingredient other than Asteraceae plant extract and Group B vitamins may be used in combination.
  • the present invention provides an extract of Asteraceae plant, preferably feverfew extract for the production of food and drink, sublimation, quasi-drug or pharmaceutical composition for promoting hair growth. Or the use of sesquiterpene ratatones, preferably parthenolides.
  • the amount of Asteraceae extract, preferably feverfew extract, or parthenolide in the use is as described above.
  • the hair growth promoting effect of the obtained food, beverage, sublimation, quasi drug or pharmaceutical composition can be further enhanced by using a group B vitamin together.
  • a group B vitamin Up The amount of Group B vitamins used in the above description is clear from the above explanation.
  • V, and other active ingredients may be used in combination!
  • the asteraceae plant extract of the present invention preferably feverfew extract, or sesquiterpene ratataton, preferably a food and drink, quasi-drug and pharmaceutical composition containing barthenolide, and the above method and use are: Can be applied not only to humans but also to animals other than humans. For example, it can be used for pets such as dogs and cats, for livestock, and for veterinary use.
  • the present invention provides, in a further aspect, an animal (non-human) feed or a veterinary pharmaceutical composition for promoting hair growth, comprising an extract of Asteraceae; the above feed wherein the Asteraceae is feverfew Or a veterinary pharmaceutical composition; and an animal (non-human) feed or veterinary pharmaceutical composition for promoting hair growth, comprising parthenolide.
  • the hair growth promoting effect can be further enhanced by combining the above-mentioned animal (non-human) feed or veterinary pharmaceutical composition with Group B vitamins.
  • Group B vitamins may be mixed with the above animal (non-human) feed or veterinary pharmaceutical composition, or may be provided separately.
  • the amount of Asteraceae extracts and Group B vitamins given to animals is the ability of veterinarians to determine appropriately.
  • the ability to be able to calculate S The above-mentioned dose for an adult with a body weight of 70 kg can be calculated from the weight of the target animal.
  • mice C3H / He Sic mice, 7 weeks old and weighing 20-30 gos, were acclimated and used for testing at 8 weeks of age.
  • the test groups were a barthenolide administration group, a feverfew extract administration group, and a control group, and 6 mice were used for each test group. 8-week-old mice were lightly anesthetized with ether, and the back was shaved with an electric clipper (THRIVE 6000AD, Natsume Seisakusho), and then an electric sieve. One (5494, BRAUN) was used to remove hair so as not to damage the skin surface. From the next day after depilation, oral administration of bartenolide, feverfew extract and control was performed.
  • Parthenolide (Sigma (purity 90% or more), lot number: 066K13 85) was suspended in 0.5% methylcellulose (400cP, Wako Pure Chemicals) aqueous solution to 40mg / 10ml in the mice of the valtenolide administration group. 10 ml / kg body weight was orally administered once a day with an oral sonde (for mice, manufactured by Fuchigami Instrument Store) and syringe (ImL capacity, manufactured by Terumo). Mice in feverfew extract administration group, feverfew extract (HAND FINE CHEMICALS Co., batch number 609M907- 235, Roh Noretenoraido content of about 0.
  • the administration period was 19 days, during which time mice were freely given solid feed MF (Oriental Yeast Co., Ltd.) and filtered tap water.
  • a digital camera COOLPIX885, Nikon
  • image analysis software Image Tool ver. 3.00, UTHSCSA
  • the ratio (%) of the regenerated hair area to the shaved area is an average of 6 animals per group.
  • mice C3H / He Sic mice, 7 weeks old and weighing 20-30 gos, were acclimated and used for testing at 8 weeks of age.
  • the test groups were a barthenolide application group, a feverfew extract application group, and a control group, and 6 mice were used for each test group. 8-week-old mice were lightly anesthetized with ether, the back was shaved with an electric clipper (THRIVE 6000AD, Natsume Seisakusho), and then the hair was removed with an electric shiver (5494, BRAUN) so as not to damage the skin surface. From the next day after depilation, Barthenolide, feverfew extract and control were applied directly to the shaved skin.
  • Parthenolide (Sigma (purity: 90% or more), lot number: 066K1385) was suspended in a 30% ethanol aqueous solution at a concentration of 4 mg / ml for the mice in the group applied with paltenolide, and a syringe (lml capacity, Terumo) 0.1 ml per animal was applied once a day using
  • feverfew extract manufactured by HAND FINE CHEMICALS, notch number 609M907-235, parthenolide content approximately 8 ⁇ 8% (w / w)
  • the suspension was suspended in a volume of 1 ml, and 0.1 ml per mouse was applied once a day using a syringe (lml capacity, Terumo).
  • the ratio (%) of the regenerated hair area to the shaved area is an average of 6 animals per group.
  • Feverfew extract powder (manufactured by HAND FINE CHEMICALS, batch number 609 M907-235, norenotenolide content about 0.8% (w / w)) wrapped in oblate, 3 times a day for 3 months 2 g per dose was given to 10 volunteers (27-64 years old, average age 4 5. 8 years old, 10 males) after each meal. Volunteers gave their scores for the following items.
  • a lotion was prepared according to Example 7 using feverfew extract powder (manufactured by HAND FINE CHEMICALS, batch number 609 M907-235, parthenolide content about 0.8% (w / w)) and 10 volunteers (42 Age-63 years old, average age 44.9 years old, 10 males) applied 10ml to the scalp 3 times a day for 3 months. Then, as in Examples 3 and 4, photographs were taken and scores were given for each item. Two people were judged not to be evaluated in this group. Figure 11 shows the photo results. Even when feverfew extract was applied, hair regeneration over time or hair growth promoting effects were observed. In this test, discomfort such as itching caused by the application of feverfew extract was swollen and other side effects were not confirmed.
  • the parthenolide was ground with a mortar and pestle, and a 30% aqueous ethanol solution was gradually added to the ground parthenolide to obtain a uniform solution.
  • a conventional fragrance may be added thereto.
  • the feverfew extract powder was ground with a mortar and pestle, and a 30% aqueous ethanol solution was gradually added to the fried feverfew extract powder to obtain a homogeneous solution.
  • a conventional fragrance or the like may be added thereto.
  • the feverfew extract powder was ground with a mortar and pestle, and petrolatum was added little by little to the fried feverfew extract powder to obtain a uniform ointment.
  • a conventional fragrance or the like may be added thereto.
  • the present invention can be used in the fields of pharmaceuticals, quasi-drugs, foods and drinks, foods for specified health use (so-called "tokuho") and supplements, particularly in the field of health foods.

Abstract

Dans l'un de ses modes de réalisation, l'invention concerne une boisson, un aliment et une composition médicinale destinés à favoriser la croissance capillaire, contenant un extrait d'un végétal appartenant à la famille des composacées ou un composé associé. En particulier, l'invention concerne une boisson, un aliment et une composition médicinale destinés à favoriser la croissance capillaire, contenant un extrait de chrisanthème matricaire ou de parthénolide. Dans un autre mode de réalisation de l'invention, celle-ci concerne une boisson, un aliment et une composition médicinale destinés à favoriser la croissance capillaire, contenant un extrait de chrisanthème matricaire ou de parthénolide associé à un élément de la famille de la vitamine B. Dans encore un autre mode de réalisation, l'invention concerne un procédé visant à favoriser la croissance capillaire à l'aide d'un extrait d'un végétal appartenant à la famille des composacées ou d'un composé associé, en particulier un extrait de chrysanthème matricaire ou de parthénolide associé à un élément de la famille de la vitamine B.
PCT/JP2007/074236 2006-12-20 2007-12-17 Boisson, aliment, alicament, composition médicinale et procédé destinés à favoriser la croissance capillaire WO2008075649A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008550140A JPWO2008075649A1 (ja) 2006-12-20 2007-12-17 発毛促進用飲食物、医薬部外品、医薬組成物ならびに発毛促進方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2006342661 2006-12-20
JP2006-342661 2006-12-20
PCT/JP2007/050913 WO2008075466A1 (fr) 2006-12-20 2007-01-22 Boisson, aliment, alicament, composition pharmaceutique et procédé destinés à favoriser la croissance capillaire
JPPCT/JP2007/050913 2007-01-22

Publications (1)

Publication Number Publication Date
WO2008075649A1 true WO2008075649A1 (fr) 2008-06-26

Family

ID=39536279

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/074236 WO2008075649A1 (fr) 2006-12-20 2007-12-17 Boisson, aliment, alicament, composition médicinale et procédé destinés à favoriser la croissance capillaire

Country Status (1)

Country Link
WO (1) WO2008075649A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014095289A3 (fr) * 2012-12-20 2014-12-31 Unilever Plc Méthode de traitement du vieillissement capillaire
JP2015196655A (ja) * 2014-03-31 2015-11-09 小林製薬株式会社 ビタミンｂ６含有組成物

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05279227A (ja) * 1992-03-31 1993-10-26 Kanebo Ltd 養毛料
JPH10512573A (ja) * 1995-01-26 1998-12-02 アシュベリー リサーチ コーポレーション セスキテルペンラクトンとビタミンｂ複合体とを含む片頭痛およびその他の疾病治療用複合剤
JP2000038340A (ja) * 1998-05-20 2000-02-08 Kumahiro Miyama 育毛剤および食品
JP2001000142A (ja) * 1999-06-23 2001-01-09 Artnature Co Ltd 育毛および発毛用栄養補助食品
JP2002518456A (ja) * 1998-06-25 2002-06-25 カート・ヘンドリクス 脳血管の正常状態を支持するための栄養補助食品
JP2003522779A (ja) * 2000-02-18 2003-07-29 エル エム デー セスキテルペンラクトン又はそのアナログを含有する育毛関連障害治療用化粧品又は医薬組成物とその調製方法
JP2004352626A (ja) * 2003-05-28 2004-12-16 Asahi Breweries Ltd 植物由来成分を含有する抗コレステロール剤

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05279227A (ja) * 1992-03-31 1993-10-26 Kanebo Ltd 養毛料
JPH10512573A (ja) * 1995-01-26 1998-12-02 アシュベリー リサーチ コーポレーション セスキテルペンラクトンとビタミンｂ複合体とを含む片頭痛およびその他の疾病治療用複合剤
JP2000038340A (ja) * 1998-05-20 2000-02-08 Kumahiro Miyama 育毛剤および食品
JP2002518456A (ja) * 1998-06-25 2002-06-25 カート・ヘンドリクス 脳血管の正常状態を支持するための栄養補助食品
JP2001000142A (ja) * 1999-06-23 2001-01-09 Artnature Co Ltd 育毛および発毛用栄養補助食品
JP2003522779A (ja) * 2000-02-18 2003-07-29 エル エム デー セスキテルペンラクトン又はそのアナログを含有する育毛関連障害治療用化粧品又は医薬組成物とその調製方法
JP2004352626A (ja) * 2003-05-28 2004-12-16 Asahi Breweries Ltd 植物由来成分を含有する抗コレステロール剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"'Parthenolide' ga 'Shukan Gendai' de Shokai Sarete Imasu, Hatsumo Ikumo Jissen BLog -Kami o Mo-ichido Hayasu", 20 September 2007 (2007-09-20), Retrieved from the Internet <URL:http://www.hairgrows.blog93.fc2.com/blog-date-200709.html> *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014095289A3 (fr) * 2012-12-20 2014-12-31 Unilever Plc Méthode de traitement du vieillissement capillaire
JP2015196655A (ja) * 2014-03-31 2015-11-09 小林製薬株式会社 ビタミンｂ６含有組成物

Similar Documents

Publication Publication Date Title
US6652891B2 (en) Co-enzyme Q10 dietary supplement
JP6745250B2 (ja) モリンガエキス
ES2857566T3 (es) Extracto de Eurycoma longifolia y su uso para mejorar y/o estimular el sistema inmunitario
KR20020087298A (ko) 야생삼을 주성분으로 함유하는 자양강장용 조성물
JP2002179586A (ja) リパーゼ阻害剤
JP2003192605A (ja) リパーゼ阻害剤
JP3768795B2 (ja) キサンチンオキシダーゼ阻害剤
JP3988168B1 (ja) イチョウ葉エキスナノ微粒子による脳細胞活性効果を有する組成物
JP2004000171A (ja) マカを含有した機能性食品
WO2008075649A1 (fr) Boisson, aliment, alicament, composition médicinale et procédé destinés à favoriser la croissance capillaire
JP2007302571A (ja) 経口用組成物
US20040097429A1 (en) Method for the reduction of the mammalian appetite
CN1195489C (zh) 沙棘精华素
JP4325908B2 (ja) 脂肪分解促進剤ならびにそれを用いた皮膚外用剤および飲食物
JP2011162504A (ja) Ａｔｐ産生促進剤、およびその利用
JP2015054836A (ja) 経口用育毛養毛剤及び育毛養毛用食品
JP2014208620A (ja) 抗肥満剤
KR20130124724A (ko) 씀바귀 추출물을 유효성분으로 포함하는 피부 노화 방지용 조성물
JP6190211B2 (ja) Ｐｄｅ３阻害剤
RU2143212C1 (ru) Биологически активная добавка
JPWO2008075649A1 (ja) 発毛促進用飲食物、医薬部外品、医薬組成物ならびに発毛促進方法
JP7162357B2 (ja) 桂皮酸誘導体の吸収促進剤
JP4328514B2 (ja) 抗アレルギー剤
JP2006306797A (ja) むくみの予防及び／又は治療用組成物
JP2001321126A (ja) 食品組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07850724

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008550140

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07850724

Country of ref document: EP

Kind code of ref document: A1